Key result
Adding etoricoxib to aspirin for 7 days significantly reduced TXM excretion and serum TXB(2) by approximately 25% in patients with essential thrombocythemia.
Why the study?
Does adding etoricoxib to aspirin reduce persistent thromboxane biosynthesis in patients with essential thrombocythemia?
Population
41 patients with essential thrombocythemia (ET) on chronic aspirin (100 mg/day) and 24 healthy subjects
Comparison
Etoricoxib added to aspirin for 7 days vs Continuing aspirin alone for 7 days
Design
RCT, randomized
Follow-up
7 days
Authors
Loading...
May explain incomplete aspirin response in ET; leaves open whether COX-2 inhibition warrants testing.
RCT (n=65)
randomized
Does adding etoricoxib to aspirin reduce persistent thromboxane biosynthesis in patients with essential thrombocythemia?
Dragani et al. (2009) conducted an RCT in Essential thrombocythemia (n=65). Etoricoxib vs. Continuing aspirin was evaluated on Urinary 11-dehydro-TXB(2) (TXM) excretion and serum TXB(2). Adding etoricoxib to aspirin for 7 days significantly reduced TXM excretion and serum TXB(2) by approximately 25% in patients with essential thrombocythemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: